Apolipoprotein A1 in Cerebrospinal Fluid Is Insufficient to Distinguish Alzheimer's Disease from Other Dementias in a Naturalistic, Clinical Setting

Nicolai Maximilian Stoye; Patrick Jung; Malena Dos Santos Guilherme; Johannes Lotz; Andreas Fellgiebel; Kristina Endres

doi:10.3233/ADR-190165

Apolipoprotein A1 in Cerebrospinal Fluid Is Insufficient to Distinguish Alzheimer's Disease from Other Dementias in a Naturalistic, Clinical Setting

J Alzheimers Dis Rep. 2020 Feb 4;4(1):15-19. doi: 10.3233/ADR-190165.

Authors

Nicolai Maximilian Stoye¹, Patrick Jung¹, Malena Dos Santos Guilherme¹, Johannes Lotz², Andreas Fellgiebel¹, Kristina Endres¹

Affiliations

¹ Department of Psychiatry and Psychotherapy, University Medical Center Johannes Gutenberg University, Mainz, Germany.
² Institute for Clinical Chemistry and Laboratory Medicine, University Medical Center Johannes Gutenberg University, Mainz, Germany.

Abstract

Apolipoprotein A1 (ApoA1) is the major protein component of the high-density lipoprotein and involved in cholesterol transport. Disruption of cholesterol homeostasis has been identified as a contributing factor for Alzheimer's disease (AD). Moreover, polymorphisms of ApoA1 have been associated with higher risk of disease onset and cognitive decline. Therefore, ApoA1 has been suggested as a biomarker in AD. Here, we tested a small cohort of AD and non-AD dementia patients and measured levels of ApoA1 in cerebrospinal fluid. Our results indicate that ApoA1 might not be applicable to distinguish AD from other forms of dementia.

Keywords: Alzheimer’s disease; Apolipoprotein A1; biomarker; cerebrospinal fluid; dementia.